{{medical}}'''细胞因子诱导的杀伤细胞'''（{{lang|en|'''Cytokine-induced killer cells''', '''CIK'''}}），又称'''细胞因子激活杀伤细胞'''，是一组[[T细胞|T细胞]]-[[自然杀伤细胞|自然杀伤细胞]]（{{lang|en|NK}}）样表型的[[适应性免疫系统|适应免疫细胞]]混合体。医生通过向[[外周血单核细胞|外周血单核细胞]]或[[脐带血|脐带血]]单核细胞中注入[[干扰素-γ|干扰素-γ]]、[[抗CD3单克隆抗体|抗CD3单克隆抗体]]、重组人体[[白细胞介素1族|白细胞介素1族]]和[[白细胞介素-2|2族]]等细胞因子诱导形成杀伤细胞。

通常情况下，免疫细胞通过识别呈递在受感染细胞表面的[[主要组织相容性复合体|主要组织相容性复合体]]（{{lang|en|MHC}}）而释放[[细胞因子|细胞因子]]，引发{{le|细胞裂解}}或[[细胞凋亡|细胞凋亡]]。然而，CIK细胞具备不受MHC分子限制的杀伤作用，能够识别未能呈递抗原或MHC的受感染细胞甚至恶性肿瘤细胞，并产生迅速及准确的免疫反应。而这些未能呈递{{lang|en|MHC}}的异常细胞不能被[[T细胞|T细胞]]识别及清除<ref name=S1>{{cite journal|last1=Schmidt-Wolf|first1=IG|last2=Negrin|first2=RS|last3=Kiem|first3=HP|last4=Blume|first4=KG|last5=Weissman|first5=IL|title=Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.|url=https://archive.org/details/sim_journal-of-experimental-medicine_1991-07-01_174_1/page/139|journal=The Journal of Experimental Medicine|date=1 July 1991|volume=174|issue=1|pages=139–49|pmid=1711560|doi=10.1084/jem.174.1.139}}</ref><ref name="S4">{{cite journal|last1=Schmidt-Wolf|first1=IG|last2=Lefterova|first2=P|last3=Mehta|first3=BA|last4=Fernandez|first4=LP|last5=Huhn|first5=D|last6=Blume|first6=KG|last7=Weissman|first7=IL|last8=Negrin|first8=RS|title=Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells.|journal=Experimental hematology|date=December 1993|volume=21|issue=13|pages=1673–9|pmid=7694868}}</ref><ref name=S3>{{cite journal|last1=Lu|first1=PH|last2=Negrin|first2=RS|title=A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.|journal=Journal of immunology (Baltimore, Md. : 1950)|date=15 August 1994|volume=153|issue=4|pages=1687–96|pmid=7519209}}</ref>。这一特殊能力，使得终末分化的CD3+CD56+ CIK细胞能够具备抗肿瘤细胞毒性，以对抗MHC限制性和非MHC限制性的癌症细胞的能力。该特征也使得CIK细胞成为治疗[[癌症|癌症]]及[[病毒感染|病毒感染]]的潜在治疗方法之一<ref name=S5>{{cite journal|last1=Pievani|first1=A|last2=Borleri|first2=G|last3=Pende|first3=D|last4=Moretta|first4=L|last5=Rambaldi|first5=A|last6=Golay|first6=J|last7=Introna|first7=M|title=Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.|journal=Blood|date=22 September 2011|volume=118|issue=12|pages=3301–10|pmid=21821703|doi=10.1182/blood-2011-02-336321}}</ref>。

== 命名与历史 ==
“细胞因子诱导的杀伤细胞”的命名，来源于终末分化的CIK细胞成熟必须通过[[细胞因子|细胞因子]]刺激。一些资料称其为“类似T细胞的自然杀伤细胞”，是因为其与[[自然杀伤细胞|自然杀伤细胞]]有密切关联。也有人主张将CIK细胞视为自然杀伤细胞的子类<ref>{{cite journal|last1=Godfrey|first1=DI|last2=MacDonald|first2=HR|last3=Kronenberg|first3=M|last4=Smyth|first4=MJ|last5=Van Kaer|first5=L|title=NKT cells: what's in a name?|journal=Nature reviews. Immunology|date=March 2004|volume=4|issue=3|pages=231–7|pmid=15039760|doi=10.1038/nri1309}}</ref>。

1991年，英戈·G·H·施密特-沃尔夫医生（G.H. Schmidt-Wolf）首次描述CIK细胞<ref name=S1/>，并在1999年开始进行癌症临床实验<ref name=S12/>。

== 机制 ==
实验证明[[淋巴细胞|淋巴细胞]]在暴露于干扰素-γ、抗CD3抗体、白细胞介素-1和白细胞介素-2后，能够裂解新鲜的、非培养的癌症细胞（包括原发性和转移性癌细胞）。CIK细胞对这些淋巴因子（特别是[[白细胞介素-2|白细胞介素-2]]）敏感，并能够裂解那些对[[NK细胞|NK细胞]]或LAK细胞活动产生抗性的肿瘤细胞。

通过抽取[[外周血|外周血]]或脐带血（比如简单的[[抽血|抽血]]），医师可以提取出[[外周血单核细胞|外周血单核细胞]]或[[脐带血|脐带血]]单核细胞。在一定时效期内，提取出来的细胞在体外暴露于干扰素-γ、抗CD3抗体、白细胞介素-1和白细胞介素-2中；这些细胞因子会强烈刺激CIK细胞的增殖和成熟<ref name=S1/><ref name="S4"/><ref name=S5/><ref>{{cite journal|last1=Introna|first1=M|last2=Pievani|first2=A|last3=Borleri|first3=G|last4=Capelli|first4=C|last5=Algarotti|first5=A|last6=Micò|first6=C|last7=Grassi|first7=A|last8=Oldani|first8=E|last9=Golay|first9=J|last10=Rambaldi|first10=A|title=Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation.|journal=Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation|date=November 2010|volume=16|issue=11|pages=1603–7|pmid=20685246|doi=10.1016/j.bbmt.2010.05.015}}</ref>。之后，成熟的CIK细胞将被回输给供体或其他异体。

== 功能 ==
因为CIK细胞可以杀死自然杀伤细胞或LAK细胞无法裂解的细胞，所以具备独特的功能。

CIK细胞同时具备[[T细胞|T细胞]]和[[NK细胞|NK细胞]]样表型特征，二者功能的独特组合，产生强有力而又广泛的不受[[MHC|MHC]]限制的抗肿瘤细胞毒性，具备广谱抗肿瘤效果<ref name="S4"/><ref name=S5/>。CIK细胞识别肿瘤的确切机制和其靶向杀伤作用尚不完全清楚。NK样细胞除了通过[[TCR|TCR]]/{{le|CD3|CD3 (immunology)}}，还通过细胞间接触依赖性的{{le|NKG2D|NKG2D}}、{{le|DNAM-1|DNAM-1}}和{{le|NKp30|NKp30}}介导来识别肿瘤。这些受体和细胞表面标志使CIK细胞能够消灭不呈递[[主要组织相容性复合体|主要组织相容性复合体]]的细胞，这点可由CIK细胞能够裂解非免疫原性、{{le|异基|allogeneic}}和{{le|同系|syngeneic}}的肿瘤细胞证明。特别是实体肿瘤细胞和血液肿瘤细胞均呈递{{le|NKG2D|NKG2D}}配体，CIK细胞能够裂解带有该标记的癌细胞。此外CIK细胞能够特异地识别肿瘤细胞和受病毒感染的细胞，而不对健康细胞做出反应<ref name=S1/><ref name="S4"/><ref name=S3/><ref name=S5/>。
 
免疫[[调节性T细胞|调节性T细胞]]会抑制CIK细胞的功能<ref name=S8>{{cite journal|last1=Li|first1=H|last2=Yu|first2=JP|last3=Cao|first3=S|last4=Wei|first4=F|last5=Zhang|first5=P|last6=An|first6=XM|last7=Huang|first7=ZT|last8=Ren|first8=XB|title=CD4 +CD25 + regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients.|journal=Journal of clinical immunology|date=May 2007|volume=27|issue=3|pages=317–26|pmid=17468835|doi=10.1007/s10875-007-9076-0}}</ref>。

== 癌症治疗的臨床試驗 ==
CIK细胞与[[白细胞介素-2|白细胞介素-2]]联合治疗癌症疗法，已经开始在小鼠和人体临床实验中进行，试验显示其[[毒性|毒性]]较低。

在大量的I期和II期[[臨床試驗|臨床試驗]]中，自体和异体CIK细胞对不同肿瘤实体显示出广谱的高毒性潜力，且只有轻微[[副作用|副作用]]。在许多案例中，CIK细胞治疗完全缓解肿瘤，延长患者生存时间并改善生活质量，甚至在癌症晚期也如此。CIK细胞治疗的使用限制于临床研究，但这种治疗方法也可能在未来进入一线治疗<ref name=S9>{{cite journal|last1=Schmeel|first1=LC|last2=Schmeel|first2=FC|last3=Coch|first3=C|last4=Schmidt-Wolf|first4=IG|title=Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC).|journal=Journal of cancer research and clinical oncology|date=8 November 2014|pmid=25381063|doi=10.1007/s00432-014-1864-3|volume=141|pages=839–49}}</ref><ref name=S10>{{cite journal|last1=Hontscha|first1=C|last2=Borck|first2=Y|last3=Zhou|first3=H|last4=Messmer|first4=D|last5=Schmidt-Wolf|first5=IG|title=Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC).|journal=Journal of cancer research and clinical oncology|date=February 2011|volume=137|issue=2|pages=305–10|pmid=20407789|doi=10.1007/s00432-010-0887-7}}</ref>。

2011年，独立机构国际CIK细胞临床实验目录（International registry on CIK cells，缩写IRCC）成立，该机构致力于收集使用CIK细胞的临床试验数据和后续分析，以描绘CIK细胞研究的最新状况，其主要侧重于评估CIK细胞治疗在临床试验中的效果和副作用。<ref name=S9/><ref name=S10/>

== 发展及挑战 ==
CIK细胞治疗仍处于临床实验阶段<ref>{{cite news|script-title=en:No proof for alleged health benefits of DC-CIK|url=http://www.scmp.com/lifestyle/health/article/1067252/no-proof-alleged-health-benefits-dc-cik|accessdate=2016-05-02|language=en|agency=South China Morning Post Publishers Ltd|date=2012-10-23|archive-date=2016-04-26|archive-url=https://web.archive.org/web/20160426090009/http://www.scmp.com/lifestyle/health/article/1067252/no-proof-alleged-health-benefits-dc-cik|dead-url=no}}</ref><ref>{{cite journal
|author1=Linn Yeh-Ching|author2=Yong Hao-Xiang|author3=Niam M|author4=Lim TJ|author5=Chu S|author6=Choong A|author7=Chuah C|author8=Goh YT|author9=Hwang W|author10=Loh Y|author11=Ng HJ|author12=Suck G|author13=Chan M|author14=Koh M.|language=en|script-title=en:A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission|journal=Cytotherapy|date=2012-08|volume=14|issue=7|pages=851-859|doi=10.3109/14653249.2012.694419}}</ref>。在临床实验中，研究人员通过[[细胞因子|细胞因子]]—[[基因|基因]]技术（例如[[白细胞介素-2|白细胞介素-2]]），成功进行了体外细胞[[转染|转染]]。CIK细胞经过基因改造，增殖率和细胞毒性显著增加<ref name=S11>{{cite journal|last1=Jäkel|first1=Clara E|last2=Schmidt-Wolf|first2=Ingo GH|title=An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells|journal=Expert Opinion on Biological Therapy|date=July 2014|volume=14|issue=7|pages=905–916|doi=10.1517/14712598.2014.900537}}</ref>。1999年，基因转染的CIK细胞首次用于已[[远端转移|转移]]的癌症治疗，共有十例患者参加此次实验<ref name=S12>{{cite journal|last1=Schmidt-Wolf|first1=IG|last2=Finke|first2=S|last3=Trojaneck|first3=B|last4=Denkena|first4=A|last5=Lefterova|first5=P|last6=Schwella|first6=N|last7=Heuft|first7=HG|last8=Prange|first8=G|last9=Korte|first9=M|last10=Takeya|first10=M|last11=Dorbic|first11=T|last12=Neubauer|first12=A|last13=Wittig|first13=B|last14=Huhn|first14=D|title=Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.|url=https://archive.org/details/sim_british-journal-of-cancer_1999-11_81_6/page/1009|journal=British Journal of Cancer|date=November 1999|volume=81|issue=6|pages=1009–16|pmid=10576658|doi=10.1038/sj.bjc.6690800}}</ref>。开始有证据显示，CIK细胞与[[树突细胞|树突细胞]]相互作用，可以进一步提高抗肿瘤疗效；而二者联合培养更可减少[[调节性T细胞|调节性T细胞]]的数量，从而使CD3+CD56+细胞群体扩增<ref>{{cite journal|last1=Märten|first1=A|last2=Ziske|first2=C|last3=Schöttker|first3=B|last4=Renoth|first4=S|last5=Weineck|first5=S|last6=Buttgereit|first6=P|last7=Schakowski|first7=F|last8=von Rücker|first8=A|last9=Sauerbruch|first9=T|last10=Schmidt-Wolf|first10=IG|title=Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations.|journal=Journal of immunotherapy (Hagerstown, Md. : 1997)|date=2000|volume=24|issue=6|pages=502–10|pmid=11759073|doi=10.1097/00002371-200111000-00007}}</ref><ref>{{cite journal|last1=Schmidt|first1=J|last2=Eisold|first2=S|last3=Büchler|first3=MW|last4=Märten|first4=A|title=Dendritic cells reduce number and function of CD4+CD25+ cells in cytokine-induced killer cells derived from patients with pancreatic carcinoma.|journal=Cancer immunology, immunotherapy : CII|date=November 2004|volume=53|issue=11|pages=1018–26|pmid=15185013|doi=10.1007/s00262-004-0554-4}}</ref>。在体外研究显示，CIK细胞在对特定肿瘤抗原有特异性的{{le|嵌合抗原受体|chimeric antigen receptor}}引导下，针对呈递这种抗原的肿瘤细胞的选择和激活能力有所增加<ref>{{cite journal|last1=Hombach|first1=AA|last2=Rappl|first2=G|last3=Abken|first3=H|title=Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".|journal=Molecular therapy : the journal of the American Society of Gene Therapy|date=December 2013|volume=21|issue=12|pages=2268–77|pmid=23985696|doi=10.1038/mt.2013.192}}</ref><ref>{{cite journal|last1=Tettamanti|first1=Sarah|last2=Marin|first2=Virna|last3=Pizzitola|first3=Irene|last4=Magnani|first4=Chiara F.|last5=Giordano Attianese|first5=Greta M. P.|last6=Cribioli|first6=Elisabetta|last7=Maltese|first7=Francesca|last8=Galimberti|first8=Stefania|last9=Lopez|first9=Angel F.|last10=Biondi|first10=Andrea|last11=Bonnet|first11=Dominique|last12=Biagi|first12=Ettore|title=Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor|journal=British Journal of Haematology|date=May 2013|volume=161|issue=3|pages=389–401|doi=10.1111/bjh.12282}}</ref>。体外实验和体内实验还表明，CIK细胞与{{le|双特异性抗体|bispecific antibodies}}（能同时与细胞毒性效应细胞和致病抗原结合的抗体）联合，活性比单独的CIK细胞要强<ref>{{cite journal|last1=Chan|first1=JK|last2=Hamilton|first2=CA|last3=Cheung|first3=MK|last4=Karimi|first4=M|last5=Baker|first5=J|last6=Gall|first6=JM|last7=Schulz|first7=S|last8=Thorne|first8=SH|last9=Teng|first9=NN|last10=Contag|first10=CH|last11=Lum|first11=LG|last12=Negrin|first12=RS|title=Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.|journal=Clinical cancer research : an official journal of the American Association for Cancer Research|date=15 March 2006|volume=12|issue=6|pages=1859–67|pmid=16551871|doi=10.1158/1078-0432.ccr-05-2019}}</ref><ref>{{cite journal|last1=Tita-Nwa|first1=F|last2=Moldenhauer|first2=G|last3=Herbst|first3=M|last4=Kleist|first4=C|last5=Ho|first5=AD|last6=Kornacker|first6=M|title=Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells.|journal=Cancer immunology, immunotherapy : CII|date=December 2007|volume=56|issue=12|pages=1911–20|pmid=17487487|doi=10.1007/s00262-007-0333-0}}</ref>。

然而，用于癌症治疗的CIK细胞临床实验很有限<ref>{{cite news|title=肿瘤免疫疗法“中外有别” 行业标准亟待完善|url=http://business.sohu.com/20150709/n416466652.shtml|accessdate=2016-05-02|agency=搜狐网|date=2015-07-09|archiveurl=https://archive.is/20160502163156/http://business.sohu.com/20150709/n416466652.shtml|archivedate=2016-05-02|deadurl=yes}}</ref><ref>{{cite book|author=Stuart H. Orkin, David E. Fisher, A. Thomas Look, Samuel Lux IV, David Ginsburg, David G. Nathan Elsevier Health Sciences|editor=Oncology of Infancy and Childhood|title=Oncology of infancy and childhood|date=2009|publisher=Saunders Elsevier|location=Philadelphia|isbn=9781437721386|pages=228|accessdate=2016-05-04}}</ref>。最根本的问题在于，以这种方法培养的免疫细胞靶向性不强<ref>{{cite journal|author1=Zhong R|coauthors=Teng J, Han B, Zhong H.|language=en|script-title=en:Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer.|journal=Cancer Immunol Immunother|date=2011-10|volume=60|issue=10|pages=1497-1502|doi=10.1007/s00262-011-1060-0|accessdate=2016-05-02|url=http://www.ncbi.nlm.nih.gov/pubmed/21681372|archive-date=2016-09-20|archive-url=https://web.archive.org/web/20160920175814/http://www.ncbi.nlm.nih.gov/pubmed/21681372|dead-url=no}}</ref>，CIK细胞无法躲过癌症的[[免疫抑制|免疫抑制]]、预后效果有限<ref>{{cite journal|author1=Shi SB1|coauthors=Ma TH, Li CH, Tang XY.|language=en|script-title=en:Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer.|journal=Tumori|date=2012-05-06|volume=98|issue=3|pages=314-319|doi=10.1700/1125.12398}}</ref>；与此同时[[CAR-T|CAR-T]]（或联合使用<ref>{{cite journal|last1=Hombach|first1=Andreas A.|last2=Rappl|first2=Gunter|last3=Abken|first3=Hinrich|coauthors=Gunter Rappl, Hinrich Abken|title=Arming cytokine induced killer cells with chimeric antigen receptors (CARs): CD28 outperforms combined CD28-OX40 "super-stimulation"|journal=Molecular Therapy|date=2013-08-28|doi=10.1038/mt.2013.192|url=http://www.nature.com/mt/journal/v21/n12/abs/mt2013192a.html|accessdate=2016-05-04|archive-date=2014-07-19|archive-url=https://web.archive.org/web/20140719004522/http://www.nature.com/mt/journal/v21/n12/abs/mt2013192a.html|dead-url=no}}</ref>）在实验中有更好的效果<ref>{{cite news|title=魏则西治疗的疑团 监管缺位背后的疗法之争|url=http://www.chinanews.com/sh/2016/05-04/7857664.shtml|accessdate=2016-05-04|agency=新京报|date=2016年5月4日|archive-date=2016-05-06|archive-url=https://web.archive.org/web/20160506053337/http://www.chinanews.com/sh/2016/05-04/7857664.shtml|dead-url=no}}</ref>。尽管对于CIK细胞及其治疗方法在学术界存有争议<ref>{{cite journal|author1=王文浩|coauthors=李贵新, 刘锦.|title=CIK 细胞在肿瘤过继细胞治疗中的疗效评价|journal=国际肿瘤学杂志|date=2013|issue=40.002|pages=106-108|url=http://www.gjzlx.cn/fileup/PDF/z2012366.pdf|accessdate=2016-05-04|archive-date=2016-08-04|archive-url=https://web.archive.org/web/20160804044737/http://www.gjzlx.cn/fileup/PDF/z2012366.pdf|dead-url=no}}</ref>，但在中国一些民营医院（[[莆田系|莆田系]]）已经以高昂收费方式进行、部分省份已将未成熟的CIK治疗纳入医保范围，2016年4月爆发的[[魏则西事件|魏则西事件]]更将CIK细胞及免疫治疗推到风口浪尖<ref>{{cite news|author1=罗朝淑|title=滥用之殇：肿瘤免疫治疗救不了魏则西|url=http://digitalpaper.stdaily.com/http_www.kjrb.com/kjrb/html/2016-05/04/content_338123.htm?div=-1|accessdate=2016-05-04|agency=科技日报|archive-date=2016-06-02|archive-url=https://web.archive.org/web/20160602092715/http://digitalpaper.stdaily.com/http_www.kjrb.com/kjrb/html/2016-05/04/content_338123.htm?div=-1|dead-url=no}}</ref>。

== 相关条目==
* [[自然杀伤T细胞|自然杀伤T细胞]]
* [[淋巴因子活化杀伤细胞|淋巴因子活化杀伤细胞]]
* [[白细胞介素|白细胞介素]]
* [[癌症免疫治疗|癌症免疫治疗]]

== 参考 ==
{{Reflist|2}}

== 外部链接 ==
* [http://www.nlm.nih.gov/cgi/mesh/2011/MB_cgi?mode=&term=Lymphokine-Activated+Killer+Cells Cytokine-Induced Killer Cells] at the US National Library of Medicine [[Medical_Subject_Headings|Medical Subject Headings]] (MeSH)
* [https://web.archive.org/web/20190413070120/http://www.cik-info.org/ International registry on CIK cells (IRCC)]
* [http://www.cancer.gov/drugdictionary?cdrid=558123 Definition of CIK cells] by the National Cancer Institute

{{Lymphocytes}}

[[Category:免疫系统|Category:免疫系统]]
[[Category:癌症治疗|Category:癌症治疗]]
[[Category:淋巴细胞|Category:淋巴细胞]]